{
    "key_points": [
        "The FDA is actively investigating the potential impacts of the new omicron COVID-19 variant on diagnostics, therapeutics, and vaccines.",
        "The agency works alongside federal partners, international regulators, and medical product companies to quickly address variant impacts.",
        "Evaluation of the omicron variant's impact on medical products is expected to be completed in the coming weeks.",
        "The FDA has monitored the emergence of SARS-CoV-2 variants throughout the pandemic and has contingency plans for new variants.",
        "Steps have been taken to adapt to emerging variants, including requiring companies to monitor and evaluate impacts on their authorized products.",
        "Previous actions include limiting use of certain monoclonal antibodies and updating healthcare providers on how variants affect therapeutics.",
        "The ongoing evaluation may determine if current vaccines need modification to combat the omicron variant effectively.",
        "Preliminary review suggests PCR and antigen tests widely used in the U.S. are likely to continue working against the omicron variant.",
        "The FDA emphasizes the importance of vaccination and boosters for protection against COVID-19, including the omicron variant.",
        "Despite the emergence of new variants, current vaccines remain highly effective at preventing severe outcomes from COVID-19."
    ],
    "spokespersons": [],
    "article_type": "government agency statement",
    "dateline": "",
    "audience": "general public",
    "stance": "neutral"
}